Health Level Seven Appoints Charles Jaffe, MD, PhD, to Role of CEO

35-year veteran of healthcare IT industry to oversee Health Level Seven’s worldwide healthcare IT standards development organization

New Orleans, LA, U.S.A. – February 26, 2007 – Health Level Seven (HL7) today announced the appointment of Charles Jaffe, MD, PhD, FACMI, as CEO effective immediately.

In his new role, Dr. Jaffe will help to define and develop the evolving organizational structure of HL7 to advance it as the leading healthcare IT standards development organization worldwide. He will drive the vision of global healthcare information interoperability among the more than two dozen countries that support HL7.

“Dr. Jaffe’s extensive experience in the healthcare IT industry will help him lead HL7 in the development of critical healthcare IT standards in the U.S. and allow us to work more closely with our numerous affiliates worldwide,” said Chuck Meyer, chair, HL7 board of directors. “We look forward to his strategic leadership continuing the momentum that HL7 has achieved in healthcare IT standards development during the past 20 years.”

As CEO of HL7, Dr. Jaffe will serve as a global ambassador and foster relationships with key standards stakeholders. He will act as HL7 industry spokesperson within the U.S. and the international community.

“I look forward to leading HL7 through the implementation of its new strategic plan and building on the critical achievements that HL7 has accomplished in its first 20 years,” said Dr. Jaffe. “There are enormous opportunities to partner with other standards development organizations, to support the global healthcare community and to forge new relationships with government agencies, industry leaders, healthcare providers and global advocates.”

Dr. Jaffe has been an active HL7 member for the past 14 years and has served in various leadership roles and on a diverse range of technical and operational committees.

-more-
Intel Corporation, where Dr. Jaffe serves as Senior Global Strategist for the Digital Health Group, will continue to support his full-time commitment as the CEO of HL7.

“HL7 has a lot of momentum and a big agenda,” said Colin Evans, director of Health Policy and Standards, Intel’s Digital Health Group. “We are pleased to be able to contribute to the advancement of healthcare technology standards by supporting Dr. Jaffe in taking on this critical role.”

Dr. Jaffe completed his medical training at Johns Hopkins and Duke Universities, and was a post-doctoral fellow at the National Institutes of Health and at Georgetown University. Dr. Jaffe has held various academic appointments, most recently in the Department of Engineering at Penn State University.

Prior to his position with Intel, he was the vice president of Life Sciences at SAIC, and the director of Medical Informatics at AstraZeneca Pharmaceuticals. Formerly, he was president of InforMed, a consultancy for research informatics. Over the course of his career, Dr. Jaffe has been the principal investigator for numerous clinical trials, and has served in various leadership roles in the American Medical Informatics Association (AMIA) and Clinical Data Interchange Standards Consortium (CDISC).

He has served as the chair of a national institutional review board, has been the contributing editor for several journals and has published on a range of subjects, including clinical management, informatics deployment and healthcare policy.

Dr. Jaffe lives in San Diego.

About HL7

Founded in 1987, Health Level Seven, Inc. (www.HL7.org) is a not-for-profit, ANSI-accredited standards developing organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7’s more than 2,400 members represent approximately 500 corporate members, including 90 percent of the largest information systems vendors serving healthcare.
HL7’s endeavors are sponsored, in part, by the support of its benefactors: Accenture; Booz Allen Hamilton, Boston Scientific Corporation, Centers for Disease Control and Prevention; Duke Clinical Research Institute (DCRI); Eclipsys Corporation; Eli Lilly & Company; Epic Systems Corporation; the Food and Drug Administration; GE Healthcare Information Technologies; GlaxoSmithKline; IBM; Intel Corporation; InterSystems Corporation; Kaiser Permanente; McKesson Provider Technologies; Microsoft Corporation; Misys Healthcare Systems; NHS Connecting for Health; NICTIZ National Healthcare; Novartis; Oracle Corporation; Partners HealthCare System, Inc.; Pfizer, Inc.; Philips Medical Systems; QuadraMed Corporation; Quest Diagnostics Inc.; Science Applications International Corporation; Siemens Medical Solutions Health Services; Solucient, LLC.; St. Jude Medical; the U.S. Department of Defense, Military Health System; the U.S. Department of Veterans Affairs; and Wyeth Pharmaceuticals.

HL7 affiliates have been established in numerous countries around the globe including Argentina, Australia, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Japan, Korea, Mexico, The Netherlands, New Zealand, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, and Uruguay.

For more information, visit www.HL7.org

###